Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Ovarian Neoplasms

  Free Subscription


29.03.2021

1 Clin Cancer Res
1 Eur J Obstet Gynecol Reprod Biol
2 J Clin Oncol
1 J Natl Cancer Inst
1 Lancet Oncol
1 Oncol Rep


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Clin Cancer Res

  1. KAZMI F, Nicum S, Roux RL, Spiers L, et al
    A Phase IB open-label, dose-escalation study of NUC1031 in combination with carboplatin for recurrent ovarian cancer.
    Clin Cancer Res. 2021 Mar 19. pii: 1078-0432.CCR-20-4403.
    PubMed         Abstract available


    Eur J Obstet Gynecol Reprod Biol

  2. GKROZOU F, Pappa C, Tsonis O, Dimitriou E, et al
    Relaxin as a potential diagnostic biomarker for ovarian cancer- A prospective study.
    Eur J Obstet Gynecol Reprod Biol. 2021;260:99-104.
    PubMed         Abstract available


    J Clin Oncol

  3. OZA AM, Lorusso D, Aghajanian C, Oaknin A, et al
    Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma.
    J Clin Oncol. 2020;38:3494-3505.
    PubMed         Abstract available

  4. MONK BJ, Grisham RN, Banerjee S, Kalbacher E, et al
    MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum.
    J Clin Oncol. 2020;38:3753-3762.
    PubMed         Abstract available


    J Natl Cancer Inst

  5. SPAAN M, van den Belt-Dusebout AW, Lambalk CB, van Boven HH, et al
    Long-Term Risk of Ovarian Cancer and Borderline Tumors After Assisted Reproductive Technology.
    J Natl Cancer Inst. 2020 Nov 17. pii: 5981708. doi: 10.1093.
    PubMed         Abstract available


    Lancet Oncol

  6. POVEDA A, Floquet A, Ledermann JA, Asher R, et al
    Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial.
    Lancet Oncol. 2021 Mar 18. pii: S1470-2045(21)00073.
    PubMed         Abstract available


    Oncol Rep

  7. ZHONG Y, Le F, Cheng J, Luo C, et al
    Triptolide inhibits JAK2/STAT3 signaling and induces lethal autophagy through ROS generation in cisplatinresistant SKOV3/DDP ovarian cancer cells.
    Oncol Rep. 2021;45.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: